NDAORALTABLET
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
4/8 — Partial
Drug data last refreshed 22h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXALT (rizatriptan benzoate) is an oral triptan approved in 1998 for acute treatment of migraine attacks and cluster headaches. It works by binding to 5-HT1B/1D serotonin receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vasoconstriction and inhibiting neuropeptide release. The mechanism provides rapid symptom relief during migraine episodes.
$1MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with minimal Part D spending signals a mature, consolidating market with contracting team investment opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with HIV
Started May 2024
2,000 enrolled
Cervical Cancer
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Started Sep 2018
118 enrolled
Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney Cancer+6 more
Impact Evaluation of Maternity Homes Access in Zambia
Started Mar 2016
4,798 enrolled
Maternal Health
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
Started Jan 2015
0Acute Myeloid Leukemia
Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
Started Sep 2014
43 enrolled
Proven or Suspected Gram-negative Bacterial InfectionPeri-operative Prophylaxis
Worked on MAXALT at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.